Law ❯ Litigation ❯ Class Action ❯ Securities Fraud

Shareholder Rights

Plaintiff Firms Intensify Biotech Securities Suits as Key Deadlines Near for Nektar, uniQure and REGENXBIO

Upcoming lead-plaintiff decisions will shape who directs these early-stage cases.

Kyndryl Securities Class Action Centers on Cash Controls as April 13 Lead‑Plaintiff Deadline Nears

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

Primo Brands Securities Class Action Nears Jan. 12 Lead-Plaintiff Deadline

Skye Bioscience Faces Investor Class Actions as Firms Court Shareholders Before Jan. 16 Deadline

CarMax Securities Suit Spurs New Investor Solicitations as Jan. 2 Lead-Plaintiff Deadline Looms

Lead-Plaintiff Deadline Nears in James Hardie Securities Case Over Alleged Inventory Misstatements

Alexandria Faces Securities Class Action Over LIC Disclosures After Q3 Write-Down

Investor Lawsuits Over Firefly Aerospace’s IPO and Rocket Setbacks Expand Ahead of Lead‑Plaintiff Deadline

Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures

KBR Investors Face Nov. 18 Deadline to Seek Lead Role in Securities Suit Over HomeSafe Disclosures

Investor Firms Press Baxter Securities Case Over Novum Pump as Dec. 15 Lead-Plaintiff Deadline Nears

SelectQuote Investor Suit Nears Oct. 10 Lead-Plaintiff Deadline

PubMatic Hit With Investor Class Action Alleging Nondisclosure of Major DSP Shift

Tesla Appeals $243 Million Autopilot Verdict and Battles Shareholders’ Robotaxi Suit